Cargando…

Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients

Introduction Thalassemia is a common genetic disorder worldwide, also occurring frequently in Karachi, Pakistan. Beta (β)-thalassemia major patients need repeated transfusions which cause iron overload. Patients are treated with chelating agents to reduce the high serum ferritin level and to decreas...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Muhammad Ali, Khan, Mahrukh A, Seedat, Ahmed M, Khan, Maria, Khuwaja, Sana F, Kumar, Ram, Usama, Syed Muhammad, Fareed, Sundus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802818/
https://www.ncbi.nlm.nih.gov/pubmed/31641562
http://dx.doi.org/10.7759/cureus.5465
_version_ 1783460864509083648
author Khan, Muhammad Ali
Khan, Mahrukh A
Seedat, Ahmed M
Khan, Maria
Khuwaja, Sana F
Kumar, Ram
Usama, Syed Muhammad
Fareed, Sundus
author_facet Khan, Muhammad Ali
Khan, Mahrukh A
Seedat, Ahmed M
Khan, Maria
Khuwaja, Sana F
Kumar, Ram
Usama, Syed Muhammad
Fareed, Sundus
author_sort Khan, Muhammad Ali
collection PubMed
description Introduction Thalassemia is a common genetic disorder worldwide, also occurring frequently in Karachi, Pakistan. Beta (β)-thalassemia major patients need repeated transfusions which cause iron overload. Patients are treated with chelating agents to reduce the high serum ferritin level and to decrease morbidity and mortality due to increased iron levels. This combined therapy also leads to some complications. One of them is the sensorineural hearing loss (SNHL). To date, no data is available in Pakistan regarding SNHL among major β-thalassemia patients on chelating therapy.  Methods A cross-sectional study was performed in collaboration with the Thalassemia Center and Dr. Ruth Pfau at the Department of Ear, Nose, and Throat, Civil Hospital, Karachi, Pakistan. The variable to detect hearing was pure tone air and bone conduction thresholds at the frequencies of 250 - 4,000 Hz. Clinical data, such as chelating agent dose, duration, and hearing status, were recorded. Demographic characteristics, like age, gender, height, and weight, were noted. The hemoglobin and serum ferritin levels of the subjects were also included. Results Forty-five percent of cases of thalassemia were suffering from SNHL. In the right ear, the Pearson correlation of chelating agent dose (mg) with SNHL was mildly positive and statistically significant (r = 0.261, p < 0.001), (r = 0.337, p < 0.001), (r = 0.198, p = 0.005), and (r = 0.207, p = 0.003) at the frequencies of 250, 500, 1,000, and 2,000 Hz, respectively, and the Pearson correlation of chelating agent used (in months) with SNHL was mildly positive and statistically significant (r = 0.232, p = 0.001), and (r = 0.301, p < 0.001) at frequencies 250 to 500 Hz, respectively. In the left ear, the Pearson correlation of chelating agent dose (mg) with SNHL was mildly positive and statistically significant, (r = 0.191, p = 0.007), (r = 0.202, p = 0.004), (r = 0.297, p < 0.001), (r = 0.183, p = 0.010) and (r = 0.221, p = 0.002) at frequencies 250, 500, 1,000, 2,000, and 4,000 Hz, respectively, and Pearson correlation of chelating agent used (months) with SNHL was mildly positive and statistically significant only at the frequency of 2,000 Hz (r = 140, p = 0.049).  Conclusion Chelation therapy and regular blood transfusions, apart from prolonging the life of thalassemic patients, also leads to some complications. With this survey, it was concluded that almost half of the patients had normal hearing, while the other half had sensorineural hearing loss after the use of deferasirox. It is inferred that the incidence of SNHL is not only dose-related but the duration of use of a chelating agent is also a contributing factor.
format Online
Article
Text
id pubmed-6802818
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-68028182019-10-22 Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients Khan, Muhammad Ali Khan, Mahrukh A Seedat, Ahmed M Khan, Maria Khuwaja, Sana F Kumar, Ram Usama, Syed Muhammad Fareed, Sundus Cureus Internal Medicine Introduction Thalassemia is a common genetic disorder worldwide, also occurring frequently in Karachi, Pakistan. Beta (β)-thalassemia major patients need repeated transfusions which cause iron overload. Patients are treated with chelating agents to reduce the high serum ferritin level and to decrease morbidity and mortality due to increased iron levels. This combined therapy also leads to some complications. One of them is the sensorineural hearing loss (SNHL). To date, no data is available in Pakistan regarding SNHL among major β-thalassemia patients on chelating therapy.  Methods A cross-sectional study was performed in collaboration with the Thalassemia Center and Dr. Ruth Pfau at the Department of Ear, Nose, and Throat, Civil Hospital, Karachi, Pakistan. The variable to detect hearing was pure tone air and bone conduction thresholds at the frequencies of 250 - 4,000 Hz. Clinical data, such as chelating agent dose, duration, and hearing status, were recorded. Demographic characteristics, like age, gender, height, and weight, were noted. The hemoglobin and serum ferritin levels of the subjects were also included. Results Forty-five percent of cases of thalassemia were suffering from SNHL. In the right ear, the Pearson correlation of chelating agent dose (mg) with SNHL was mildly positive and statistically significant (r = 0.261, p < 0.001), (r = 0.337, p < 0.001), (r = 0.198, p = 0.005), and (r = 0.207, p = 0.003) at the frequencies of 250, 500, 1,000, and 2,000 Hz, respectively, and the Pearson correlation of chelating agent used (in months) with SNHL was mildly positive and statistically significant (r = 0.232, p = 0.001), and (r = 0.301, p < 0.001) at frequencies 250 to 500 Hz, respectively. In the left ear, the Pearson correlation of chelating agent dose (mg) with SNHL was mildly positive and statistically significant, (r = 0.191, p = 0.007), (r = 0.202, p = 0.004), (r = 0.297, p < 0.001), (r = 0.183, p = 0.010) and (r = 0.221, p = 0.002) at frequencies 250, 500, 1,000, 2,000, and 4,000 Hz, respectively, and Pearson correlation of chelating agent used (months) with SNHL was mildly positive and statistically significant only at the frequency of 2,000 Hz (r = 140, p = 0.049).  Conclusion Chelation therapy and regular blood transfusions, apart from prolonging the life of thalassemic patients, also leads to some complications. With this survey, it was concluded that almost half of the patients had normal hearing, while the other half had sensorineural hearing loss after the use of deferasirox. It is inferred that the incidence of SNHL is not only dose-related but the duration of use of a chelating agent is also a contributing factor. Cureus 2019-08-22 /pmc/articles/PMC6802818/ /pubmed/31641562 http://dx.doi.org/10.7759/cureus.5465 Text en Copyright © 2019, Khan et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Khan, Muhammad Ali
Khan, Mahrukh A
Seedat, Ahmed M
Khan, Maria
Khuwaja, Sana F
Kumar, Ram
Usama, Syed Muhammad
Fareed, Sundus
Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients
title Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients
title_full Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients
title_fullStr Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients
title_full_unstemmed Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients
title_short Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients
title_sort sensorineural hearing loss and its relationship with duration of chelation among major β-thalassemia patients
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802818/
https://www.ncbi.nlm.nih.gov/pubmed/31641562
http://dx.doi.org/10.7759/cureus.5465
work_keys_str_mv AT khanmuhammadali sensorineuralhearinglossanditsrelationshipwithdurationofchelationamongmajorbthalassemiapatients
AT khanmahrukha sensorineuralhearinglossanditsrelationshipwithdurationofchelationamongmajorbthalassemiapatients
AT seedatahmedm sensorineuralhearinglossanditsrelationshipwithdurationofchelationamongmajorbthalassemiapatients
AT khanmaria sensorineuralhearinglossanditsrelationshipwithdurationofchelationamongmajorbthalassemiapatients
AT khuwajasanaf sensorineuralhearinglossanditsrelationshipwithdurationofchelationamongmajorbthalassemiapatients
AT kumarram sensorineuralhearinglossanditsrelationshipwithdurationofchelationamongmajorbthalassemiapatients
AT usamasyedmuhammad sensorineuralhearinglossanditsrelationshipwithdurationofchelationamongmajorbthalassemiapatients
AT fareedsundus sensorineuralhearinglossanditsrelationshipwithdurationofchelationamongmajorbthalassemiapatients